255 related articles for article (PubMed ID: 20515459)
1. Alterations in osteoclast function and phenotype induced by different inhibitors of bone resorption--implications for osteoclast quality.
Neutzsky-Wulff AV; Sørensen MG; Kocijancic D; Leeming DJ; Dziegiel MH; Karsdal MA; Henriksen K
BMC Musculoskelet Disord; 2010 Jun; 11():109. PubMed ID: 20515459
[TBL] [Abstract][Full Text] [Related]
2. Diphyllin, a novel and naturally potent V-ATPase inhibitor, abrogates acidification of the osteoclastic resorption lacunae and bone resorption.
Sørensen MG; Henriksen K; Neutzsky-Wulff AV; Dziegiel MH; Karsdal MA
J Bone Miner Res; 2007 Oct; 22(10):1640-8. PubMed ID: 17576165
[TBL] [Abstract][Full Text] [Related]
3. Psoralen and Bakuchiol Ameliorate M-CSF Plus RANKL-Induced Osteoclast Differentiation and Bone Resorption Via Inhibition of AKT and AP-1 Pathways in Vitro.
Chai L; Zhou K; Wang S; Zhang H; Fan N; Li J; Tan X; Hu L; Fan X
Cell Physiol Biochem; 2018; 48(5):2123-2133. PubMed ID: 30110702
[TBL] [Abstract][Full Text] [Related]
4. Osteoclasts degrade bone and cartilage knee joint compartments through different resorption processes.
Löfvall H; Newbould H; Karsdal MA; Dziegiel MH; Richter J; Henriksen K; Thudium CS
Arthritis Res Ther; 2018 Apr; 20(1):67. PubMed ID: 29636095
[TBL] [Abstract][Full Text] [Related]
5. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.
Michael H; Härkönen PL; Väänänen HK; Hentunen TA
J Bone Miner Res; 2005 Dec; 20(12):2224-32. PubMed ID: 16294275
[TBL] [Abstract][Full Text] [Related]
6. A specific subtype of osteoclasts secretes factors inducing nodule formation by osteoblasts.
Henriksen K; Andreassen KV; Thudium CS; Gudmann KN; Moscatelli I; Crüger-Hansen CE; Schulz AS; Dziegiel MH; Richter J; Karsdal MA; Neutzsky-Wulff AV
Bone; 2012 Sep; 51(3):353-61. PubMed ID: 22722081
[TBL] [Abstract][Full Text] [Related]
7. Actin polymerization modulates CD44 surface expression, MMP-9 activation, and osteoclast function.
Samanna V; Ma T; Mak TW; Rogers M; Chellaiah MA
J Cell Physiol; 2007 Dec; 213(3):710-20. PubMed ID: 17508356
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro.
Michael H; Härkönen PL; Kangas L; Väänänen HK; Hentunen TA
Br J Pharmacol; 2007 Jun; 151(3):384-95. PubMed ID: 17420779
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of osteoclast mediated bone resorption--rationale for the design of new therapeutics.
Väänänen K
Adv Drug Deliv Rev; 2005 May; 57(7):959-71. PubMed ID: 15876398
[TBL] [Abstract][Full Text] [Related]
10. Degradation of the organic phase of bone by osteoclasts: a secondary role for lysosomal acidification.
Henriksen K; Sørensen MG; Nielsen RH; Gram J; Schaller S; Dziegiel MH; Everts V; Bollerslev J; Karsdal MA
J Bone Miner Res; 2006 Jan; 21(1):58-66. PubMed ID: 16355274
[TBL] [Abstract][Full Text] [Related]
11. Interaction between effects of parathyroid hormone and bisphosphonate on regulation of osteoclast activity by the osteoblast-like cell line UMR-106.
Yu X; Schøller J; Foged NT
Bone; 1996 Oct; 19(4):339-45. PubMed ID: 8894139
[TBL] [Abstract][Full Text] [Related]
12. Activation of dimeric glucocorticoid receptors in osteoclast progenitors potentiates RANKL induced mature osteoclast bone resorbing activity.
Conaway HH; Henning P; Lie A; Tuckermann J; Lerner UH
Bone; 2016 Dec; 93():43-54. PubMed ID: 27596806
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonate-osteoclasts: changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients.
Jobke B; Milovanovic P; Amling M; Busse B
Bone; 2014 Feb; 59():37-43. PubMed ID: 24211427
[TBL] [Abstract][Full Text] [Related]
14. Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity.
El Hajj Dib I; Gallet M; Mentaverri R; Sévenet N; Brazier M; Kamel S
Eur J Pharmacol; 2006 Dec; 551(1-3):27-33. PubMed ID: 17049513
[TBL] [Abstract][Full Text] [Related]
15. Different Blood-Borne Human Osteoclast Precursors Respond in Distinct Ways to IL-17A.
Sprangers S; Schoenmaker T; Cao Y; Everts V; de Vries TJ
J Cell Physiol; 2016 Jun; 231(6):1249-60. PubMed ID: 26491867
[TBL] [Abstract][Full Text] [Related]
16. Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand.
Udagawa N; Takahashi N; Jimi E; Matsuzaki K; Tsurukai T; Itoh K; Nakagawa N; Yasuda H; Goto M; Tsuda E; Higashio K; Gillespie MT; Martin TJ; Suda T
Bone; 1999 Nov; 25(5):517-23. PubMed ID: 10574571
[TBL] [Abstract][Full Text] [Related]
17. Resting T cells negatively regulate osteoclast generation from peripheral blood monocytes.
Shinoda K; Sugiyama E; Taki H; Harada S; Mino T; Maruyama M; Kobayashi M
Bone; 2003 Oct; 33(4):711-20. PubMed ID: 14555277
[TBL] [Abstract][Full Text] [Related]
18. Improved methods for testing antiresorptive compounds in human osteoclast cultures.
Rissanen JP; Ylipahkala H; Fagerlund KM; Long C; Väänänen HK; Halleen JM
J Bone Miner Metab; 2009; 27(1):105-9. PubMed ID: 19018457
[TBL] [Abstract][Full Text] [Related]
19. In vitro differentiation of CD14 cells from osteopetrotic subjects: contrasting phenotypes with TCIRG1, CLCN7, and attachment defects.
Blair HC; Borysenko CW; Villa A; Schlesinger PH; Kalla SE; Yaroslavskiy BB; Garćia-Palacios V; Oakley JI; Orchard PJ
J Bone Miner Res; 2004 Aug; 19(8):1329-38. PubMed ID: 15231021
[TBL] [Abstract][Full Text] [Related]
20. AP-002: A novel inhibitor of osteoclast differentiation and function without disruption of osteogenesis.
Wang Y; Mei Y; Song Y; Bachus C; Sun C; Sheshbaradaran H; Glogauer M
Eur J Pharmacol; 2020 Dec; 889():173613. PubMed ID: 33007291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
